Aggarwal Megha, Sharma Rajesh, Kumar Pravindra, Parida Manmohan, Tomar Shailly
Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee-247667, India.
Division of Virology, Defence Research and Development Establishment, Gwalior 474002, India.
Sci Rep. 2015 Oct 6;5:14753. doi: 10.1038/srep14753.
Chikungunya virus (CHIKV) capsid protein (CVCP) is a serine protease that possesses cis-proteolytic activity essential for the structural polyprotein processing and plays a key role in the virus life cycle. CHIKV being an emerging arthropod-borne pathogenic virus, is a public health concern worldwide. No vaccines or specific antiviral treatment is currently available for chikungunya disease. Thus, it is important to develop inhibitors against CHIKV enzymes to block key steps in viral reproduction. In view of this, CVCP was produced recombinantly and purified to homogeneity. A fluorescence resonance energy transfer (FRET)-based proteolytic assay was developed for high throughput screening (HTS). A FRET peptide substrate (DABCYL-GAEEWSLAIE-EDANS) derived from the cleavage site present in the structural polyprotein of CVCP was used. The assay with a Z' factor of 0.64 and coefficient of variation (CV) is 8.68% can be adapted to high throughput format for automated screening of chemical libraries to identify CVCP specific protease inhibitors. Kinetic parameters Km and kcat/Km estimated using FRET assay were 1.26 ± 0.34 μM and 1.11 × 10(3) M(-1) sec(-1) respectively. The availability of active recombinant CVCP and cost effective fluorogenic peptide based in vitro FRET assay may serve as the basis for therapeutics development against CHIKV.
基孔肯雅病毒(CHIKV)衣壳蛋白(CVCP)是一种丝氨酸蛋白酶,具有结构多蛋白加工所必需的顺式蛋白水解活性,在病毒生命周期中起关键作用。CHIKV作为一种新兴的节肢动物传播致病病毒,是全球公共卫生关注的问题。目前尚无针对基孔肯雅病的疫苗或特异性抗病毒治疗方法。因此,开发针对CHIKV酶的抑制剂以阻断病毒繁殖的关键步骤很重要。鉴于此,重组生产并纯化了CVCP至同质状态。开发了一种基于荧光共振能量转移(FRET)的蛋白水解测定法用于高通量筛选(HTS)。使用了一种源自CVCP结构多蛋白中切割位点的FRET肽底物(DABCYL-GAEEWSLAIE-EDANS)。该测定法的Z'因子为0.64,变异系数(CV)为8.68%,可适用于高通量形式,用于自动筛选化学文库以鉴定CVCP特异性蛋白酶抑制剂。使用FRET测定法估计的动力学参数Km和kcat/Km分别为1.26±0.34μM和1.11×10(3)M(-1)sec(-1)。活性重组CVCP的可用性和基于成本效益高的荧光肽的体外FRET测定法可能为开发针对CHIKV的治疗方法奠定基础。